Bone Fracture and the Interaction Between Bisphosphonates and Proton Pump Inhibitors: a Meta-analysis

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Jul 2

PMID 26131063

Citations 9

Authors

Si-Dong Yang

Qian Chen

Hai-Kun Wei

Feng Zhang

Da-Long Yang

Yong Shen

Wen-Yuan Ding

Affiliations

Soon will be listed here.

Abstract

Objective: Recent studies suggested an increased risk of fractures with interaction between bisphosphonates (BPs) and proton pump inhibitors (PPIs). We performed a meta-analysis of fractures between patients taking BPs/PPIs and those taking BPs only.

Methods: We conducted a PubMed database and Ovid database search, as well as Cochrane Library search (up to July 2014) for studies assessing the association between fractures and BPs or/and PPIs. We performed random effects meta-analysis of odds ratios (OR) according to fracture type and conducted subgroup analyses by race and BP subtypes. Heterogeneity was assessed using Q statistics and I(2) statistic.

Results: After study selection, 4 unique studies (5 comparisons) including 57259 patients were available for this meta-analysis. Pooled analysis of overall fracture risk of BP+PPI group versus BP group showed a significant increase in risk of fractures (OR = 1.52, P = 0.025), with substantial heterogeneity. However, heterogeneity was drastically reduced in subgroup of Asian (I(2) = 24% and P = 0.251), and fracture risk showed a significant increase (OR = 1.75, P = 0.026). In contrast, heterogeneity was little eliminated in subgroup of European, and fracture risk was no statistical difference (OR = 1.42, P = 0.068). Three studies including 4 comparisons reported on spine fracture were included in the pooled analysis demonstrating an increased spine fracture risk associated with BP/PPI interaction (OR = 1.60, 95% CI 1.13-2.26, P = 0.008, I(2) = 58.6%).

Conclusions: This meta-analysis suggests that there is an interaction associated with increased fracture risk (particularly for spine and Asian race) between BP and PPI use. Clinicians should carefully evaluate such risk factors for osteoporosis in patients taking BPs, before routinely prescribing PPIs, and make a careful judgment as to whether PPIs may be safe for patients at high risk of fractures.

Citing Articles

Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.

Dutta A, Jain A, Jearth V, Mahajan R, Panigrahi M, Sharma V Indian J Gastroenterol. 2023; 42(5):601-628.

PMID: 37698821 DOI: 10.1007/s12664-023-01428-7.

Surgical Procedures Used for Correction of Scheuermann's Kyphosis: A Meta-Analysis.

Li Q Pain Res Manag. 2021; 2021:2142964.

PMID: 34725561 PMC: 8557059. DOI: 10.1155/2021/2142964.

Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.

Desai B, Qadri M, Vyas B Eur J Clin Pharmacol. 2021; 78(1):35-41.

PMID: 34714373 DOI: 10.1007/s00228-021-03237-3.

Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts.

Kruger T, Herlofson B, Lian A, Syversen U, Reseland J Bone Rep. 2021; 14:100750.

PMID: 33553512 PMC: 7856318. DOI: 10.1016/j.bonr.2021.100750.

Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature.

Briganti S, Naciu A, Tabacco G, Cesareo R, Napoli N, Trimboli P Int J Endocrinol. 2021; 2021:8902367.

PMID: 33510787 PMC: 7822697. DOI: 10.1155/2021/8902367.

References

Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid M, Judge A, Nogues X . Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2013; 29(1):268-74. PMC: 3867340. DOI: 10.1002/jbmr.2011. View

Roux C, Goldstein J, Zhou X, Klemes A, Lindsay R . Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2011; 23(1):277-84. DOI: 10.1007/s00198-011-1574-5. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Gray S, LaCroix A, Larson J, Robbins J, Cauley J, Manson J . Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010; 170(9):765-71. PMC: 4240017. DOI: 10.1001/archinternmed.2010.94. View

Biswas P, Wilton L, Shakir S . Pharmacovigilance study of alendronate in England. Osteoporos Int. 2003; 14(6):507-14. DOI: 10.1007/s00198-003-1399-y. View

Abrahamsen B, Eiken P, Eastell R . Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011; 171(11):998-1004. DOI: 10.1001/archinternmed.2011.20. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Targownik L, Lix L, Leung S, Leslie W . Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2009; 138(3):896-904. DOI: 10.1053/j.gastro.2009.11.014. View

Roughead E, McGeechan K, Sayer G . Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol. 2004; 57(6):813-6. PMC: 1884527. DOI: 10.1111/j.1365-2125.2004.02078.x. View

10.

Kwok C, Yeong J, Loke Y . Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2010; 48(4):768-76. DOI: 10.1016/j.bone.2010.12.015. View

11.

Yu E, Blackwell T, Ensrud K, Hillier T, Lane N, Orwoll E . Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008; 83(4):251-9. PMC: 2596870. DOI: 10.1007/s00223-008-9170-1. View

12.

Itoh S, Sekino Y, Shinomiya K, Takeda S . The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2012; 31(2):206-11. DOI: 10.1007/s00774-012-0406-9. View

13.

Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):1896-900. DOI: 10.1016/s0140-6736(99)04149-5. View

14.

Farina C, Gagliardi S . Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des. 2002; 8(23):2033-48. DOI: 10.2174/1381612023393369. View

15.

Lin Z, Wang J, Chung C, Huang P, Su B, Cheng K . Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan National Cohort Study. Bone. 2014; 64:235-9. DOI: 10.1016/j.bone.2014.04.017. View

16.

Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C . Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002; 91(3):474-9. DOI: 10.1159/000064290. View

17.

Hosking D, Geusens P, Rizzoli R . Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM. 2005; 98(6):403-13. DOI: 10.1093/qjmed/hci070. View

18.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt B, Leufkens H . Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2010; 22(3):903-10. PMC: 3034906. DOI: 10.1007/s00198-010-1337-8. View

19.

Samuelsson A, Hakanson R, Persson P . Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997; 61(3):210-5. DOI: 10.1007/s002239900325. View

20.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View